具有免疫反应性的猪瘟病毒多表位基因在大肠杆菌中的克隆表达和鉴定

将猪瘟病毒不同抗原表位基因串联构成重组基因BT21,化学合成后克隆至pMD18-T载体中,然后再将BT21串联基因片段插入原核表达载体pGEX-6P-1。经酶切和测序鉴定后,构建的重组质粒pGEX—BT21转化大肠杆菌BL21（DE3）,通过IPTG诱导表达,表达产物进行SDS—PAGE分析,用G1utathione Se-pharose4B亲和层析法纯化目的蛋白和Western blot分析其免疫学活性。结果表明：融合蛋白GST—BT21以可溶形式表达,分子量约为33kDa,与预期大小相符,纯化的重组蛋白可被猪瘟病毒阳性血清所识别,具有良好的免疫学活性。从而为进一步研究该融合蛋白的免疫特性和功能奠定了基础。     

TFAR19促进小鼠肝线粒体膜通透性转运孔的开放

TFAR19基因 (TF 1cellapoptosisrelatedgene 19)是北京大学人类疾病基因中心从人白血病细胞株TF 1细胞中克隆到的凋亡相关新基因之一 (GenBank登记号AF0 1495 5 )。初步研究发现 ,该基因在细胞凋亡时高表达 ,并且表达产物具有抑制肿瘤细胞生长和促进凋亡作用。但是其确切的作用机制不明。线粒体膜完整性破坏所导致促凋亡因子 (如细胞色素c等因子 )的释放是细胞凋亡关键性的控制因素。线粒体膜通透性转运孔 (PTP) ,对线粒体膜完整性具有重要的调控作用。研究了重组人TFAR19蛋白在体外条件下 ,对线粒体PTP、跨膜电位 ,以及细胞色素c释放的影响。结果表明 ,TFAR19蛋白使分离的小鼠肝线粒体PTP开放、线粒体跨膜电位下降 ,以及细胞色素c释放。TFAR19对线粒体的上述作用是通过促进PTP开放起作用的。实验结果提示 ,TFAR19对线粒体凋亡信号有正反馈放大作用 ,并进一步揭示了TFAR19促进细胞凋亡的机制     

靶向抗肿瘤蛋白iRGD-CDD的原核表达及生物活性鉴定

目的: 原核表达并纯化具有特异性成纤维细胞激活蛋白(FAPα)酶切位点的靶向抗肿瘤GP-CDD-iRGD融合蛋白,利用FAPα的酶切功能切除融合标签,检测其对FAPα阳性肿瘤细胞株的毒性。方法: 设计并合成GP-CDD-iRGD基因,插入pGEX-4T3 载体,构建重组表达质粒,转化至BL21大肠杆菌感受态细胞中,IPTG诱导表达,SDS-PAGE分析重组融合蛋白的表达,Western blot检测融合蛋白的表达,经GST亲和柱纯化融合蛋白后,通过体外细胞毒性试验(MTT法)和细胞凋亡实验评价该融合蛋白的靶向抗肿瘤活性。结果: 成功构建重组原核表达质粒pGEX-GP-CDD-iRGD,可溶性表达相对分子量约为36 kDa的融合蛋白GST-GP-CDD-iRGD,纯化后蛋白纯度约为90%,经MTT实验测定其对FAPα阳性4T1细胞株的ED50约为18.5μmol/L,流式细胞术检测到其对FAPα阳性4T1细胞株具有选择性毒性作用,早期凋亡比例达到约28%。结论: 原核表达的重组融合蛋白GP-CDD-iRGD对FAPα阴性4T1细胞株未显示毒性,而对FAPα阳性4T1细胞株具有显著的促凋亡作用,为进一步研究其在体内的靶向抗肿瘤活性提供了依据。     

口蹄疫病毒P1基因在大肠杆菌中的高效表达及其生物活性的初步分析

将口蹄疫病毒 (FMDV)结构蛋白基因P1的完整cDNA序列插入原核表达性载体pGEX KG中 ,使P1基因与GST融合 ,获得融合表达质粒pKG P1,转化E .coliBL₂₁ (DE3) ,经IPTG诱导 ,SDS PADE结果表明GST P1融合蛋白获得高效表达 ,Western blot检测证实表达的融合蛋白具有免疫学活性 ,表达产物主要存在于细菌裂解液上清中。进一步采用GST纯化试剂盒纯化P1蛋白并作为诊断抗原 ,建立了P1 ELISA诊断方法 ,与FMD间接血凝 (IHA)检测方法平行检测 86 4份血清样品 ,总的符合率达87%。     

甘蓝型油菜BnCOP1基因的原核表达和纯化

COP1蛋白是植物光信号调节网络中介导光信号转导的一个关键因子,对植物生长发育起重要调控作用.通过RT-PCR方法从甘蓝型油菜中克隆BnCOP1基因编码区全长序列,并将其连接到冷诱导原核表达载体pCold TF上,构建原核重组表达载体pCold TF/BnCOP1,转化大肠杆菌BL(21)star.通过IPTG法低温诱导表达融合蛋白.结果表明,重组质粒在大肠杆菌中获得高效表达,融合蛋白分子质量约为128 kD,融合蛋白在上清液和包涵体中均有表达,可溶性部分经亲和层析纯化和Western blotting检测证实获得了高纯度的重组蛋白,这些结果为进一步研究油菜BnCOP1的结构和功能奠定了基础.     

小鼠TAp63γ及两种突变体的原核表达、纯化和DNA结合活性

采用PCR扩增法得到小鼠TAp63γ野生型及两种缺失突变体的cDNA,3种cDNA与表达载体pGEX-2TK重组构建成GST融合表达质粒并转化感受态E.coli BL21 (DE3),经IPTG诱导了小鼠TAp63γ野生型及两种缺失突变体的可溶性表达. 诱导表达的菌液经离心收集菌体、超声破碎及Triton X-100增溶后获得可溶性表达蛋白粗提液. 利用Glutathione Sepharose 4 Fast Flow亲合层析纯化出电泳均一的3种GST融合蛋白. 凝胶滞留分析证实仅野生型小鼠TAp63γ蛋白能特异结合p53靶序列,经序列比对及同源建模分析,表明小鼠TAp63γ DBD结合区的完整性、关键氨基酸的保守性及三维结构的相似性可能是其DNA结合活性所必需的.     

PTD融和蛋白的原核表达及其抗体制备

目的:为制备凋亡素重组蛋白抗体,首先获得凋亡素重组蛋白融合基因LTA,而且通过原核表达系统表达重组蛋白并制备其抗体,为进一步利用凋亡素重组蛋白导向治疗肿瘤的检测奠定基础.方法:应用重叠延伸的基因融合技术将LHRH(黄体生成激素释放激素)基因、TAT(HIV-1反式转录激活因子)基因和凋亡素基因重组,构建成凋亡素重组蛋白原核表达载体pET-28a-LTA,随后将表达质粒转入BL21菌株,经IPTG诱导表达重组融合蛋白,将已表达的重组蛋白通过Ni-NTA亲和色谱柱进行纯化,并制备LTA凋亡素重组蛋白抗体.结果:表达产物经聚丙烯酰胺凝胶电泳检测,LTA蛋白融合基因获得高效表达,凝胶薄层扫描分析表明表达蛋白占菌体蛋白12.6%.LTA蛋白经Ni-NTA亲和色谱柱柱纯化,以纯化蛋白为抗原免疫獭兔制备凋亡素重组蛋白抗血清.结果表明抗体的效价为1: 12800.结论:应用重叠延伸的基因融合技术获得凋亡素重组蛋白融合基因LTA,通过原核表达系统表达重组蛋白并制备其抗体.     

人博卡病毒2型VP1U突变对sPLA2活性的影响

对HBoV2 VP1U蛋白进行原核表达并检测其sPLA_2活性,对其关键氨基酸进行突变,检测突变对sPLA_2活性的影响。构建重组质粒pMD18T-VP1U,选取VP1U蛋白4个关键氨基酸为突变点,分别进行原核表达,蛋白纯化后用sPLA_2试剂盒检测sPLA_2活性,对比突变前后VP1U蛋白sPLA_2活性有无变化。野生型HBoV2VP1U蛋白的sPLA_2活性为0.243μmol/min/mL,具有sPLA_2活性;突变体L19P、P21R、D42H及Y45N蛋白的sPLA_2活性分别为野生型蛋白的1.2%、1.2%、0.82%、0.41%。野生型HBoV2VP1U蛋白具有sPLA_2活性,突变体蛋白均几乎完全丧失了sPLA_2活性,提示19、21、42、45位4个氨基酸是维持sPLA_2活性的关键氨基酸。该研究为靶向抗病毒药物的研究提供了理论基础。     

人乳头瘤病毒16型L1蛋白的克隆及表达

采用PCR技术从宫颈癌组织中扩增人乳头瘤病毒16型(Human papillomavirus type16,HPV16)L1全长基因片段,目的片段克隆到pMD18T载体后经酶切鉴定及测序确认。构建重组原核表达质粒pGEX4T1-L1,转化大肠杆菌E.coliBL21,IPTG诱导表达出以非可溶性蛋白形式存在的表达蛋白,该重组蛋白的表达量占菌体总蛋白的17%,免疫印迹检测表明,表达蛋白与宫颈癌病人血清出现特异性反应。成功构建了重组原核表达质粒pGEX4T1-L1,并且在原核细胞中得到表达,为进一步研究L1蛋白的免疫学活性及疫苗的研发奠定了基础。     

人GST-14-3-3σ融合蛋白的原核表达、纯化及活性检测

目的:构建人14-3-3σ基因的原核表达载体,获得其原核表达产物,并对融合蛋白进行纯化及活性检测。方法:采用PCR技术从人乳腺文库中扩增14-3-3σ基因编码序列,将其克隆到pGEX-KG载体中,重组质粒转化大肠杆菌Rossate后表达重组蛋白,利用GST-Sepharose 4B亲和珠对原核表达产物进行纯化,并通过SDS-PAGE和Western印迹检测融合蛋白的表达,采用GST pull-down技术检测已纯化的蛋白与已知体外相互作用蛋白AKT之间的相互作用。结果:从人乳腺文库中扩增获得约750 bp的DNA片段,并成功克隆至pGEX-KG载体上,经双酶切鉴定得到与预期片段大小相符的外源基因插入片段,测序与目的基因序列完全一致;在Rossate菌株中诱导表达出相对分子质量约52 000的目的蛋白,SDS-PAGE和Western印迹结果表明融合蛋白表达成功,并纯化得到GST-14-3-3σ融合蛋白;通过GST pull-down技术检测证实GST-14-3-3σ融合蛋白可以和AKT在体外结合,并证实其具有生物学活性。结论:获得了原核表达的活性较好的GST-14-3-3σ蛋白,为后续研究细胞周期蛋白调控机制奠定了实验基础。     

Soluble expression in Escherichia coli,purification and characterization of a human TF-1 cell apoptosis-related protein TFAR19

A novel human TF-1 cell apoptosis-related protein, TFAR19, cloned from a human leukemia cell line, TF-1, was first overexpressed in Escherichia coli with the sequence Met-Gly-His(6)-Gly-Thr-Asn-Gly, a hexahistidine sequence followed by a hydroxylamine cleavage site attached to its amino terminus. The resulting protein was soluble and single-step purified to homogeneity by metal chelating affinity chromatography. After cleavage of the purified His(6)-tagged TFAR19 sample with hydroxylamine, highly purified untagged TFAR19 protein was then obtained through an FPLC Resource Q column. The structural characteristics and function of the His(6)-tagged and untagged TFAR19 proteins were studied using circular dichroism, intrinsic fluorescence, and ANS-binding fluorescence spectra and apoptosis activity assay. The results show that alpha-helix is the main secondary structure of the proteins and the two forms of TFAR19 protein fold properly, which correspond well to their apoptosis activity expression. The results also indicate that the extra sequence including the His(6)-tag fused to the N-terminus of TFAR19 protein has a minimal effect on its structure and function, suggesting that the His(6)-tagged TFAR19 protein could be further used as an immobilized target for finding potential proteins which interact with TFAR19 from a cDNA library using in vitro ribosome display technique.     

Effects of TFAR19 gene on the growth and biorheological properties of mouse erythroleukemia cell line MEL

Apoptosis is a genetically controlled program of cellular self-destruction, which plays a key role in the development and homeostasis of virtually all animals. In recent years, Liu et al.[1] found a novel apoptosis-related gene TFAR19 (TF-1 cells apoptosis-related gene 19). It is conserved in evolution and distributed extensively in tissues. The related study showed that its coding protein is probably very important for the signal transduction in cell nucleus, regulating the cell proliferat…     

Transfer of anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation can inhibit the apoptosis

Electroporation has been successfully used for the introduction of DNA, RNA, oligonucleotide and protein into eukaryotic and prokaryotic cells for the transformation and expression of various gene products. TFAR19 (TF-1 apoptosis-related gene 19), also designated PDCD5 (Programmed Cell Death 5), is cloned as an increased expression gene during the apoptotic process of TF-1 cell induced by cytokine withdrawal. It facilitates rather than induces apoptosis in different cell lines. To explore its molecular mechanism, we successfully transferred the anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation and observed the apoptosis process of HeLa cells induced by etoposide with flow cytometry. We demonstrate that the introduction of anti-TFAR19 antibody can suppress the apoptosis accelerating effect of TFAR19 in its natural environment. This study shows that TFAR19 may be a critical factor for apoptosis; and transfer of monoclonal antibody into mammalian cells by in situ electroporation is a useful method to study the function of endogenous factors.     

TFAR19 gene changes the biophysical properties of murine erythroleukemia cells

TFAR19 is a novel apoptosis-related gene and can accelerate cell apoptosis in the presence of apoptosis inducements. Here, we studied the effects of TFAR19 on some biophysical properties of mouse erythroleukemia (MEL) cells and their molecular and structural basis. After transfected with TFAR19 and apoptosis inducement, MEL revealed a high cell membrane fluidity, a decrease in resynthesis of phospholipids, an increase in the proteins/nucleic acids ratio, a relatively orderly cytoskeleton network, an impaired deformability, a low integrin aM expression, and a decrease in adhesion to endothelial cells. These findings suggest the potential of TFAR19 for antitumor cell migration, and thus for antitumor gene therapy.     

抗人CD19单链抗体基因的构建、表达及功能测定

采用RT-PCR方法从分泌抗人类白细胞表面分化抗原CD19单克隆抗体的杂交瘤细胞中克隆出V_H和V_L可变区基因,再通过重叠延伸拼接（spliceoverlap extension）PCR方法在V_H和V_L可变区基因之间引入连接肽(Gly4Ser)3,体外构建抗人CD19单链抗体（抗CD19-ScFv）基因。将其克隆至表达载体PET28a并在大肠杆菌中表达。SDS-PAGE和Westernblot分析结果表明,抗CD19-ScFv在BL21（DE3）菌中获得表达,重组蛋白的相对分子量为27kD,表达产物以不溶性包涵体形式存在,经过溶解包涵体,镍柱亲和层析纯化和体外复性过程,获得了高纯度的单链抗体片段。流式细胞分析结果证实抗CD19ScFv可与人类白细胞表面的分化抗原CD19结合,保留了鼠源性单抗与CD19结合活性。抗人CD19-ScFv的构建与表达,为下一步针对B淋巴系统恶性肿瘤的靶向治疗奠定了基础。     

Effects of <Emphasis Type="Italic">TFAR19</Emphasis> gene on the growth and biorheological properties of mouse erythroleukemia cell line MEL

Using the method of gene transfection with liposome, we obtained the mouse erythroleukemia cell line MEL-TF19, which stably carries TFAR19, a novel apoptosis-related gene. The expression of TFAR19 was detected by Western blot. Growth curve and flow cytometry analysis showed that after being transfected with TFAR19 gene, the growth of MEL-TF19 is suppressed and its apoptosis is accelerated because of the serum deprivation. Our biorheological study indicated that in the apoptotic process, compared with MEL cells, MEL-TF19 cells exhibit larger osmotic fragility, lower cell surface charge density, increased elastic modulus K1 which is inversely proportional to cells' maximal deformation ability, obviouslydiminished surface viscosity μ, with elastic modulus K2 having no distinct changes. The above results provided some bases for recognizing the function of TFAR19 completely from the viewpoint of biorheology.     

Effects of TFAR19 gene on the growth and biorheological properties of mouse erythroleukemia cell line MEL

Using the method of gene transfection with liposome, we obtained the mouse erythroleukemia cell line MEL-TF19, which stably carries TFAR19, a novel apoptosis-related gene. The expression of TFAR19 was detected by Western blot. Growth curve and flow cytometry analysis showed that after being transfected with TFAR19 gene, the growth of MEL-TF19 is suppressed and its apoptosis is accelerated because of the serum deprivation. Our biorheological study indicated that in the apoptotic process, compared with MEL cells, MEL-TF19 cells exhibit larger osmotic fragility, lower cell surface charge density, increased elastic modulus K ₁ which is inversely proportional to cells’ maximal deformation ability, obviously diminished surface viscosity μ, with elastic modulus K ₂having no distinct changes. The above results provided some bases for recognizing the function of TFAR19 completely from the viewpoint of biorheology.     

Hv古细菌SRP19基因的克隆、表达、重组蛋白的纯化及生物学活性的研究

目的：构建Hv古细菌SRP19蛋白的表达载体pET23d-HvSRP19并在大肠杆菌中表达后进行纯化和研究其生物学活性,为研究SRP循环的分子机制奠定基础。方法：用体外合成的重组DNA技术,先合成具有重叠碱基的10个寡核苷酸短序列,通过拼接,获得Hv SRP19基因全长DNA后,克隆到pET23d载体上。重组质粒在大肠杆菌BL21（DE3）pLysS中的大量表达产物经Q-Sepharose离子交换层析柱纯化后再用蔗糖密度梯度超速离心法分析其生物学活性。结果：正确构建了pET23d-Hv SRP19表达载体,并在大肠杆菌BL21（DE3）pLysS中获得良好的表达;成功地纯化了表达产物,纯度达95%;证明了具有SRP19蛋白的生物学活性,能够与Hv SRP RNA相互作用形成SRP19-SRP RNA的复合物。结论：纯化的Hv SRP19蛋白与Hv SRP RNA相互作用所形成的复合物,被认为是启动SRP颗粒形成和功能发挥的开始。     

EpCAM蛋白的表达、纯化及其单克隆抗体的制备

目的:原核表达EpCAM蛋白并制备抗EpCAM特异性单克隆抗体,初步鉴定相应单克隆抗体的特性。方法:PCR扩增EpCAM基因胞外区,将目的基因亚克隆至载体pET-28a(+),转化至大肠埃希菌株BL21,IPTG诱导表达,组氨酸亲和层析法纯化表达产物。纯化蛋白免疫BALB/c小鼠,将成功免疫的小鼠脾细胞与骨髓瘤SP2/0细胞融合,经ELISA筛选得到分泌特异性抗EpCAM的单克隆抗体的细胞株,免疫BALB/c小鼠进一步制备相应的单克隆抗体,并通过Western blot(蛋白质印记)和FACS(流式细胞分析)鉴定单抗的特异性及生物学活性。结果:成功构建重组表达载体pET28a-EpCAM并在大肠杆菌中获得表达,经His-tag亲和层析法获得纯化的EpCAM重组蛋白。EpCAM重组蛋白免疫的BALB/c小鼠的脾细胞与SP2/0细胞融合、筛选,获得两株稳定分泌EpCAM抗体的杂交瘤细胞株,分别命名为4B2、2F2并免疫BALB/c小鼠获得相应的单克隆抗体。Western blot结果显示4B2腹水纯化所得单抗能够识别FaDu细胞系(人咽鳞癌细胞)中的EpCAM蛋白,但2F2未能识别FaDu细胞中的变性的EpCAM蛋白。FACS结果显示两者均能和FaDu细胞中天然的EpCAM蛋白结合。讨论:成功制备了抗EpCAM的单克隆抗体,并能够识别人咽鳞癌细胞系FaDu中表达的EpCAM,为进一步研究EpCAM抗体在肿瘤治疗中的作用提供基础。